Abeona Therapeutics Inc. (0H7R.L)
USD 4.84
(8.52%)
USD 4.84
(8.52%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -50.57 Million USD | -12.86% |
| 2022 | -34.38 Million USD | 23.11% |
| 2021 | -76.8 Million USD | -23.32% |
| 2020 | -74.51 Million USD | 37.29% |
| 2019 | -67.6 Million USD | -22.59% |
| 2018 | -55.8 Million USD | -105.96% |
| 2017 | -27.09 Million USD | -17.52% |
| 2016 | -23.05 Million USD | -30.85% |
| 2015 | -13.96 Million USD | -464.74% |
| 2014 | -3.12 Million USD | 17.92% |
| 2013 | -3.8 Million USD | 2.46% |
| 2012 | -9.5 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -16.19 Million USD | 133.93% |
| 2024 Q1 | -13.6 Million USD | -89.72% |
| 2023 Q3 | -10.58 Million USD | 1.84% |
| 2023 FY | - USD | -10.62% |
| 2023 Q2 | -10.78 Million USD | 3.31% |
| 2023 Q4 | -12.48 Million USD | -18.0% |
| 2023 Q1 | -11.15 Million USD | -1.58% |
| 2022 FY | - USD | 23.11% |
| 2022 Q3 | -8.29 Million USD | -2.43% |
| 2022 Q2 | -8.09 Million USD | 39.16% |
| 2022 Q1 | -13.31 Million USD | -2.46% |
| 2022 Q4 | -10.97 Million USD | -32.33% |
| 2021 Q2 | -12.61 Million USD | 6.63% |
| 2021 Q4 | -12.99 Million USD | 5.79% |
| 2021 Q3 | -13.78 Million USD | -9.29% |
| 2021 Q1 | -13.51 Million USD | 0.94% |
| 2021 FY | - USD | -23.32% |
| 2020 Q3 | -5.4 Million USD | 53.63% |
| 2020 Q2 | -11.64 Million USD | 11.97% |
| 2020 FY | - USD | 37.29% |
| 2020 Q1 | -13.23 Million USD | 7.73% |
| 2020 Q4 | -13.64 Million USD | -152.55% |
| 2019 Q2 | -21.91 Million USD | -26.0% |
| 2019 Q4 | -14.33 Million USD | 8.18% |
| 2019 Q3 | -15.61 Million USD | 28.75% |
| 2019 FY | - USD | -22.59% |
| 2019 Q1 | -17.39 Million USD | -4.68% |
| 2018 Q1 | -10.5 Million USD | -22.14% |
| 2018 Q3 | -16.41 Million USD | -33.78% |
| 2018 Q4 | -16.61 Million USD | -1.27% |
| 2018 FY | - USD | -105.96% |
| 2018 Q2 | -12.26 Million USD | -16.73% |
| 2017 Q3 | -5.22 Million USD | 36.55% |
| 2017 Q2 | -8.23 Million USD | -63.55% |
| 2017 Q1 | -5.03 Million USD | 9.85% |
| 2017 FY | - USD | -17.52% |
| 2017 Q4 | -8.6 Million USD | -64.7% |
| 2016 Q3 | -4.95 Million USD | 24.21% |
| 2016 FY | - USD | -30.85% |
| 2016 Q4 | -5.58 Million USD | -12.76% |
| 2016 Q2 | -6.53 Million USD | -9.15% |
| 2016 Q1 | -5.98 Million USD | 1.92% |
| 2015 Q4 | -6.1 Million USD | -1.5% |
| 2015 Q2 | -3.99 Million USD | -112.05% |
| 2015 Q1 | -1.88 Million USD | -311.35% |
| 2015 FY | - USD | -464.74% |
| 2015 Q3 | -6.01 Million USD | -50.51% |
| 2014 FY | - USD | 17.92% |
| 2014 Q4 | -458 Thousand USD | 27.53% |
| 2014 Q2 | -702.5 Thousand USD | 47.07% |
| 2014 Q3 | -632 Thousand USD | 10.04% |
| 2014 Q1 | -1.32 Million USD | -94.33% |
| 2013 FY | - USD | 2.46% |
| 2013 Q1 | -502 Thousand USD | 43.66% |
| 2013 Q2 | -1.92 Million USD | -282.67% |
| 2013 Q3 | -695 Thousand USD | 63.82% |
| 2013 Q4 | -683 Thousand USD | 1.73% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | -891 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.468% |
| Dynavax Technologies Corporation | 9.66 Million USD | 623.195% |
| Illumina, Inc. | -608 Million USD | 91.682% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 101.553% |
| Biogen Inc. | 2.37 Billion USD | 102.128% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 88.737% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 104.344% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 88.485% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 151.466% |
| Waters Corporation | 1.02 Billion USD | 104.947% |
| Perrigo Company plc | 646.2 Million USD | 107.826% |
| uniQure N.V. | -253.1 Million USD | 80.019% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 85.361% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 45.078% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 80.988% |
| bluebird bio, Inc. | -167.16 Million USD | 69.747% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 57.015% |
| Imunon, Inc. | -20.78 Million USD | -143.342% |
| Myriad Genetics, Inc. | -67.8 Million USD | 25.41% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 112.154% |
| Nektar Therapeutics | -243.1 Million USD | 79.198% |
| Editas Medicine, Inc. | -163.11 Million USD | 68.996% |
| Verastem, Inc. | -83.16 Million USD | 39.191% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.552% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -13.807% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 51.276% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -35.644% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 116.299% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 42.155% |
| Evolus, Inc. | -41.81 Million USD | -20.957% |
| Adicet Bio, Inc. | -136.53 Million USD | 62.96% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 42.522% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.087% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 66.31% |
| FibroGen, Inc. | -261.4 Million USD | 80.654% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 103.016% |
| OPKO Health, Inc. | -65.51 Million USD | 22.81% |
| Homology Medicines, Inc. | -47.75 Million USD | -5.897% |
| Geron Corporation | -174.78 Million USD | 71.066% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 77.831% |
| Exelixis, Inc. | 196.6 Million USD | 125.723% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 49.843% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 9.298% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 90.012% |
| Zoetis Inc. | 3.68 Billion USD | 101.372% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 77.523% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.098% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -40.159% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 78.013% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 146.686% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 111.19% |
| Blueprint Medicines Corporation | -474.61 Million USD | 89.345% |
| Insmed Incorporated | -654.73 Million USD | 92.276% |
| TG Therapeutics, Inc. | 26.1 Million USD | 293.762% |
| Incyte Corporation | 919.42 Million USD | 105.5% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 89.992% |